Therapeutic effect of withania somnifera on pristane-induced model of SLE

被引：24

作者：

Ujla Minhas

Ranjana Minz

Prabir Das

Archana Bhatnagar

机构：

[1] Department of Biochemistry, Basic Medical Sciences Block, Panjab University

[2] Department of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh

来源：

Inflammopharmacology | 2012年 / 20卷 / 4期

关键词：

Autoantibodies; Immune-complexes; Immunomodulatory properties; Inflammation; Pristane-induced model of SLE; Withania somnifera;

D O I：

10.1007/s10787-011-0102-8

中图分类号：

学科分类号：

摘要：

Systemic lupus erythematosus commonly known as lupus is an intricate disorder with multiple organ involvement characterized primarily by inflammation caused due to deposition of immune-complexes formed by production of autoantibodies against nuclear, nucleolar as well as cytoplasmic self-antigens. Lack of availability of suitable treatments or treatments that are only symptomatic calls for investigation of possible modalities. Withania somnifera with its immunomodulatory properties is prescribed for arthritis in ayurveda. In the present study, the therapeutic effect of Withania somnifera pure root powder (at 1,000 and 500 mg/kg body weight) on pristane-induced Balb/c model of lupus was investigated to elucidate its remedial outcome on SLE. SLE-like symptoms are produced in the model of lupus: production of autoantibodies, proteinuria, nephritis as well as immune-complex deposition along with various other inflammatory markers such as formation of lipogranuloma, production of pro-inflammatory cytokines including interleukin-6 and tumor necrosis factor-a, nitric oxide and reactive oxygen species. Withania somnifera was found to have potent inhibitory effect on proteinuria, nephritis and other inflammatory markers. Humoral response, however, was found to be impervious. The potent reduction in inflammation in the present model of lupus suggests further investigation of this herb for its possible therapeutic use in SLE. © Springer Basel AG 2011.

引用

页码：195 / 205

页数：10

共 37 条

[1]

Aalinkeel R., Hu Z., Nair B.B., Sykes D.E., Reynolds J.L., Mahajan S.D., Et al., Genomic analysis highlights the role of the JAKSTAT signaling in the anti-proliferative effects of dietary flavonoid-'Ashwagandha' in prostate cancer cells, Evid Based Complement Altern Med, 7, pp. 177-187, (2010)

[2]

Amara S., Kumar S.P., Athota R.R., Suppressive effect of Withania somnifera root extract on the induction of anti-ovalbumin IgE antibody response in mice, Pharmaceutical Biology, 37, 4, pp. 253-259, (1999)

[3]

Bhatnagar M., Sharma D., Salvi M., Neuroprotective effects of Withania somnifera dunal.: A possible mechanism, Neurochem Res, 34, pp. 1975-1983, (2009)

[4]

Burns J.J., Zhao L., Taylor E.W., Spelman K., The influence of traditional herbal formulas on cytokine activity, Toxicology, 278, pp. 140-159, (2010)

[5]

Calero I., Sanz I., Targeting B cells for the treatment of SLE: The beginning of the end or the end of the beginning?, Discov Med, 10, pp. 416-424, (2010)

[6]

Calvani N., Caricchio R., Tucci M., Sobel E.S., Silvestris F., Tartaglia P., Richards H.B., Induction of apoptosis by the hydrocarbon oil pristane: Implications for pristane-induced lupus, Journal of Immunology, 175, 7, pp. 4777-4782, (2005)

[7]

Chatterjee S., Srivastava S., Khalid A., Singh N., Sangwan R.S., Sidhu O.P., Et al., Comprehensive metabolic fingerprinting of Withania somnifera leaf and root extracts, Phytochemistry, 71, pp. 1085-1094, (2010)

[8]

Chopra A., Lavin P., Patwardhan B., Chitre D., A 32-week randomized, placebo-controlled clinical evaluation of RA-11, an Ayurvedic drug, on osteoarthritis of the knees, Journal of Clinical Rheumatology, 10, 5, pp. 236-245, (2004)

[9]

Christina A.J.M., Joseph D.G., Packialakshmi M., Kothai R., Robert S.J.H., Chidambaranathan N., Ramasamy M., Anticarcinogenic activity of Withania somnifera Dunal against Dalton's Ascitic Lymphoma, Journal of Ethnopharmacology, 93, 2-3, pp. 359-361, (2004)

[10]

Davis L., Kuttan G., Effect of withania somnifera on cytokine production in normal and cyclophosphamide treated mice, Immunopharmacol Immunotoxicol, 21, pp. 695-703, (1999)

← 1 2 3 4 →